Jacob Plieth shares his thoughts on MorphoSys, Syndax, Poseida, Arcellx, Autolus, Cogent, Dizal, and more.

Dr. Maus comments on CD19 lupus data, the recent FDA note on malignancies, and the work her lab is doing for brain and heme cancers.

Madeleine Armstrong shares her thoughts on CAR-T data in lupus, the menin inhibitor class, BCMA CAR-T, and Regeneron's bi-specifics.

Mara Goldstein previews key #ASH23 data from Incyte, Syndax, Autolus, Corvus, IN8bio, and more.

Greg Yap describes how his firm evaluates AI companies and lists other technology transformations to watch in the sector.

Surbhi Sarna explains how Y Combinator invests in healthcare and biotech entrepreneurs and how the application process works.

Nevan Krogan, Director of the Quantitative Biosciences Institute at UCSF, expands on work posted to bioRxiv today.

Andy Hsieh comments on AbbVie's buyout of ImmunoGen, gives a deep dive into radiopharmaceutical, and discusses AASLD, Seagen, and Icosavax.

Simeon George talks about his firm's philosophy, advice for biotech entrepreneurs, and discusses a busy few weeks of news.

Jakob Dupont says he is focused on clinical stage companies or ones that are months within IND.

Evan Seigerman discusses news from #AHA23, what's going on with Structure, Verve's polarizing result, Neurocrine, Vertex, Pfizer and more.

Paul Matteis comments on Biogen and Vertex earnings, discusses recent news on BioMarin and Sage.

Amanda Burkhardt describes how phages selectively target bacteria of interest and how PHIOGEN's platform is designed for broad spectrum.

Angela Holmes explains how her company uses computational power to help companies with drug development.

Raphaël Ognar discusses the results we have seen in the NK space over recent years.

Imran Alibhai describes how Tvardi is taking the approach of using a non-covalent inhibitor to prevent the activation of STAT3.

CPRIT Deputy Executive Officer and General Counsel Kristen Doyle explains the details of this Texas cancer research funding program.

Jochen Reiser talks about the reach of UTMB and the science happening in Galveston, and highlights immunology approaches to kidney disease.

Omid Veiseh explains the idea behind Rice's Biotech Launchpad, describes the cytokine company Avenge Bio, and talks about other technologies

Bill McKeon describes TMC's news campus that is focused on translational research.